You used to have a sex drive. It wasn't something you thought about. Then, sometime in your late 30s or early 40s, it started feeling like something you had to search for. Nothing about your relationship or circumstances changed. The desire just ... dimmed. And when you mentioned it at your appointment, you got a nodding acknowledgement and no follow-up plan.
Reduced libido in perimenopause is so common it's almost treated as background noise. But it has identifiable hormonal drivers and — this is the part most women aren't told — there are genuine treatment options. You don't have to just accept it.
What's actually driving it hormonally
Estrogen decline gets most of the attention in the perimenopause conversation, but the testosterone picture is just as important for libido. Testosterone in women is produced by the ovaries and adrenal glands. It peaks in the mid-20s and declines gradually — so by the time perimenopause begins, many women already have meaningfully lower testosterone than they did a decade earlier, and the ovarian transition accelerates that decline.
Testosterone acts directly on brain receptors involved in sexual desire, arousal, and the reward circuitry that drives wanting. Lower testosterone correlates with lower spontaneous desire — the kind that arises without prompting. This is different from responsive desire (desire that develops in response to arousal), which tends to be more preserved. The distinction matters for treatment.
A 2019 global consensus statement on women's testosterone use — signed by experts from ISSWSH, the Menopause Society, and the British Menopause Society — concluded that there is good evidence for testosterone therapy improving sexual desire, arousal, orgasm, and satisfaction in postmenopausal women. The statement also noted that testosterone is not approved by the FDA for women in the US (though it is available off-label) while it is approved in some other countries. The consensus confirmed that blood levels used in women should fall within the normal premenopausal female range — not the male range. Side effects at appropriate doses are generally mild and reversible.
The physical layer: GSM and pain
Reduced desire and painful or uncomfortable sex often coexist in perimenopause — and it's worth separating them. If sex has become physically uncomfortable due to vaginal dryness, reduced lubrication, or increased sensitivity, that changes the desire picture independently of testosterone. You can't properly assess whether low testosterone is driving low desire if sex also hurts.
Addressing GSM first — with vaginal estrogen, moisturizers, or lubricants — is often step one in the treatment sequence, because it removes a significant behavioral inhibitor that overlays the hormonal picture.
Spontaneous desire (wanting sex out of the blue) is testosterone-driven and more common in younger people. Responsive desire (desire that emerges once you're in a sexual context) is more common in women in long-term relationships and increases in perimenopause relative to spontaneous. Neither is more normal or healthy. Many women think something is wrong because they've lost spontaneous desire — but if responsive desire is present, the relationship with sexuality isn't gone. It's changed.
What the treatment options actually are
This is an area where the options have improved, and where a proper conversation with a menopause-informed clinician is worth seeking out. The right approach depends on whether the primary driver is testosterone decline, GSM, mood and stress, relationship context, or a combination.
Testosterone (off-label in the US): Compounded topical testosterone at low doses, applied to the inner wrist or thigh, has good evidence for improving desire in postmenopausal and perimenopausal women. It's used off-label in the US because no product is FDA-approved specifically for women. Ask for it by name. A menopause specialist is more likely to be comfortable prescribing it than a general OB-GYN.
HRT (estrogen/progesterone): Helps with GSM and mood, which improves the context for sexual response. It doesn't consistently restore testosterone-driven spontaneous desire, but it removes the physical barriers. Many women find that addressing GSM and night-sweat-disrupted sleep makes a material difference to their overall interest in sex.
Flibanserin (Addyi): Approved for premenopausal HSDD. Works on serotonin and dopamine pathways in the brain. Requires daily dosing and has real drug interactions (alcohol, CYP3A4 inhibitors). The evidence shows modest effect. Worth discussing if other options aren't suitable.
Bremelanotide (Vyleesi): Self-injected on-demand (45 minutes before sex). Approved for premenopausal HSDD. Works on melanocortin receptors. Side effects include transient nausea and facial flushing. Evidence shows meaningful improvement in desire scores in clinical trials.
Sex therapy / psychosexual counseling: Especially effective when relationship, stress, or body image factors are contributing. Not instead of hormonal treatment — alongside it when relevant.
Mindfulness-based approaches: A 2021 systematic review found that mindfulness interventions improved sexual desire, arousal, and satisfaction in women with HSDD. The mechanism involves reducing performance anxiety and increasing present-moment attention during sex. Worth trying and genuinely evidence-based.
What to bring to your appointment
- "I'm experiencing significant reduction in sexual desire — I'd like to discuss whether testosterone therapy might be appropriate for me"
- "Can we test my testosterone levels alongside estrogen and FSH?" — a baseline before any hormonal treatment is standard practice
- "I'm also experiencing vaginal discomfort during sex — can we address both issues, and which one should we treat first?"
- If you're not getting answers: ask for a referral to a menopause specialist or a sexual medicine physician — these clinicians are significantly more likely to have current knowledge of treatment options
A note from our medical advisors
Many women are told that reduced libido in perimenopause is "just part of aging" and that nothing can be done. This is not current evidence. The 2019 global consensus statement on testosterone in women was clear: there is good evidence for treatment, and women should not be left to manage this without options. Bring the conversation to your doctor explicitly. If your current provider doesn't engage with it, a menopause specialist is worth seeking out.
References
- Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660–4666. PubMed 31498871
- Shifren JL, et al. Sexual Problems and Distress in United States Women: Prevalence and Correlates. Obstet Gynecol. 2008;112(5):970–978. PubMed 18978095
- Basson R. The female sexual response: A different model. J Sex Marital Ther. 2000;26(1):51–65. PubMed 10693116
- Brotto LA, et al. A mindfulness-based cognitive therapy intervention for women with sexual interest/arousal disorder. J Sex Med. 2021;18(10):1712–1724. PubMed 34426117